Current possibilities of immunotherapy for malignant melanoma

03/2018

MUDr. Jindřich Kopecký, Ph.D.; MUDr. Ondřej Kubeček

Klinika onkologie a radioterapie LF UK a FN Hradec Králové

SUMMARY

Thanks to gradually improving understanding of complex interactions between the immune system and cancer and thanks to deeper understanding of molecular interactions between tumour and immune cells at the level of so-called checkpoint inhibitors, there has been a renaissance of immunotherapy as a therapeutic modality in oncology in recent years. The following article focuses on the current status of checkpoint inhibitors for therapy of malignant melanoma and other possibilities for their use in the future.

KEY WORDS

melanoma, immunotherapy, checkpoint inhibitors, nivolumab, ipilimumab, pembrolizumab